
CureVac COVID-19 vaccine hits just 48% efficacy in final analysis
Fox News
German biotech company CureVac announced its COVID-19 vaccine demonstrated 48% efficacy against COVID-19 of any severity in a final readout of late-stage trial data.
Results in older age groups were inconclusive. Further findings suggested variants of concern (VOC) were behind the majority of COVID-19 cases in the late-stage trial, with just 3% of cases tied to the original strain. The low efficacy comes in contrast to Pfizer and Moderna's mRNA COVID-19 vaccines with over 90% efficacy and only somewhat diminished protection in the face of viral variants.More Related News

Pizza before tomatoes? Ancient Rome's version of America's favorite food looked nothing like today's
Ancient Rome pizza at Hungary restaurant features no tomatoes or mozzarella, using garum fish sauce and olive paste. Neverland Pizzeria's dish is limited-edition.












